Labcorp (LH) director awarded 773 RSUs vesting in 2027

Rhea-AI Filing Summary

Labcorp Holdings Inc. director Peter M. Neupert reported an equity award under a company plan. On February 10, 2026, he received 773 Restricted Stock Units (RSUs) at a price of $0 per unit. Each RSU represents the right to receive one share of Labcorp common stock.

The RSUs vest fully on February 10, 2027, meaning he will receive the underlying shares if vesting conditions are met. After this grant, Neupert beneficially owns 1,670 RSUs in total, all held as direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NEUPERT PETER M

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/10/2026		A		773		(2)	(2)	Common Stock	773	$0	1,670(3)	D

Explanation of Responses:

1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

2. The Restricted Stock Units vest fully on February 10, 2027.

3. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Peter M. Neupert	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Labcorp (LH) report for Peter M. Neupert?

Labcorp director Peter M. Neupert reported an award of 773 Restricted Stock Units on February 10, 2026. These RSUs were granted at $0 per unit as equity compensation, not as an open-market share purchase.

How many Labcorp (LH) RSUs did Peter M. Neupert receive and when do they vest?

Peter M. Neupert received 773 Restricted Stock Units on February 10, 2026. According to the filing, these RSUs vest in full on February 10, 2027, after which he will receive one share of common stock for each vested unit.

What does each Restricted Stock Unit in the Labcorp (LH) Form 4 represent?

Each Restricted Stock Unit reported represents the contingent right to receive one share of Labcorp Holdings Inc. common stock. Once the RSUs vest, the director will receive the corresponding number of Labcorp shares without paying an exercise price.

How many Labcorp (LH) Restricted Stock Units does Peter M. Neupert own after this grant?

Following the February 10, 2026 grant, Peter M. Neupert beneficially owns 1,670 Restricted Stock Units. This figure reflects the aggregate number of RSUs he holds directly, including the newly awarded 773 units disclosed in the Form 4.

Was the Labcorp (LH) RSU transaction a stock purchase by Peter M. Neupert?

No, the transaction was an equity award, not a market purchase. The Form 4 lists transaction code "A" for a grant or other acquisition, and the 773 Restricted Stock Units were issued at a price of $0 per unit as compensation.